Mederma correction
This article was originally published in The Rose Sheet
Executive Summary
A story that ran in the July 20 issue of "The Rose Sheet" wrongly identified anti-scarring as a $30 mil. market opportunity. According to Merz Pharmaceuticals, which recently launched Mederma Stretch Marks Therapy, the market for stretch-mark treatments is worth $30 mil., while the larger anti-scarring business is valued at roughly $55 mil. "The Rose Sheet" regrets the error. Also, to be clear, the "roughly half of women" who have been "dissatisfied" with products formulated to reduce the appearance of stretch marks were polled before Mederma Stretch Marks Therapy became available to them